Poor Reporting of Scientific Leadership Information in Clinical Trial Registers
2008

Poor Reporting of Scientific Leadership Information in Clinical Trial Registers

Sample size: 1388 publication Evidence: moderate

Author Information

Author(s): Melanie Sekeres, Jennifer L. Gold, An-Wen Chan, Joel Lexchin, David Moher, Marleen L. P. Van Laethem, James Maskalyk, Lorraine Ferris, Nathan Taback, Paula A. Rochon

Primary Institution: Kunin-Lunenfeld Applied Research Unit, Baycrest, Toronto, Ontario, Canada

Hypothesis

What proportion of registered clinical trials provide valid scientific leadership information?

Conclusion

Many clinical trials fail to provide required scientific leadership and contact information, undermining accountability.

Supporting Evidence

  • 74% of trial entries listed the name of the study chair or principal investigator.
  • 51% of non-industry funded trials provided e-mail contact information.
  • Industry funded trials were less likely to provide scientific leadership information.

Takeaway

The study found that many clinical trials don't list who is in charge or how to contact them, which is important for trust.

Methodology

The study reviewed clinical trial entries from ISRCTN and ClinicalTrials.gov to assess compliance with registration requirements.

Potential Biases

The sample may not reflect the broader issues in clinical trial registration due to its focus on Canadian trials.

Limitations

The study focused only on trials with Canadian investigators, which may not represent global compliance.

Participant Demographics

The study included clinical trials with Canadian investigators.

Statistical Information

P-Value

p<0.0001

Confidence Interval

95% CI: 95–701

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0001610

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication